3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
2
Phase EARLY_PHASE1
1
Phase 1
1
Status
Recruiting
3
Active not recruiting
2
Unknown
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
70
Nivolumab
36
Cyclophosphamide
34
Carboplatin
28
Dexamethasone
23
Specimen Handling
22
Paclitaxel
22
Lenalidomide
22
durvalumab
19
Radiotherapy
19
Gemcitabine
19
venetoclax
18
Magnetic Resonance Spectroscopy
18
Doxorubicin
17
Rituximab
16
fludarabine
15
Ipilimumab
15
Bevacizumab
15
Cisplatin
14
Biopsy
14
atezolizumab
13
Etoposide
13
Vincristine
12
Pemetrexed
12
belantamab mafodotin
11
Docetaxel
11
Calcium Dobesilate
11
Azacitidine
11
olaparib
10
Oxaliplatin
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Active not recruiting
×
defactinib
×
Clear all
NCT05074810
2026-01-12
RAMP203
Verastem, Inc.
Phase 1/2
Active not recruiting
153 enrolled
NCT05669482
2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2
Active not recruiting
40 enrolled